To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
TolerogenixX has a patented technology that can be used to suppress unwanted immune responses in the body. This novel cell therapy will revolutionize the treatment of transplant recipients and numerous autoimmune diseases. The idea to develop an alternative treatment to standard immunosuppression emerged from a desire to treat post-transplant patients and those suffering from numerous autoimmune diseases, not with a non-specific suppression of their natural immune responses, but to specifically address the underlying problem. Conventional immunosuppressive medication is associated with a large number of harmful side effects and often results in premature death of patients.
Science4Life Venture Cup 2015
Basis of the TolerogenixX method
In organ transplantations as well as in autoimmune diseases, the immune system recognizes tissues and organs as non-self and reacts against it. The current medical answer is standard immunosuppression. This treatment must be performed throughout and has considerable disadvantages, such as increased infections and tumor risks, as well as high costs.
The subject of the TolerogenixX method is the specific suppression of the immune reaction in the sense of an individualized (tailored) immunosuppression. The impact of the TolerogenixX method is increased effectiveness, avoidance of adverse side effects of standard immunosuppression and decisive cost advantage.
Using the patented treatment of white blood cells, the TolerogenixX method achieves a tailored immunomodulation for the individual patient.